IBRS19182 / CAPItello-291 / Ajay Dhakal
Research Question:
What is the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the
treatment of patients with advanced breast cancer following recurrence or progression
on or after aromatase inhibitor (AI) therapy?
Basic Study Information
Purpose:
Phase III, double-blind, randomised study assessing the efficacy of capivasertib +
fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced
(inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression
on or after AI therapy.
Location: University of Rochester Medical Center
Study Reference #: IBRS19182
Lead Researcher (Principal Investigator)
Lead Researcher:
Ajay Dhakal
Study Contact Information
Study Coordinator: Lauren Mitchell
Email: lauren_mitchell@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search